Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a hold rating to a buy rating in a research note released on Saturday.

Other equities analysts also recently issued research reports about the company. HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Barclays cut their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday. Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday. Finally, Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $797.75.

Read Our Latest Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $759.24 on Friday. The stock has a market capitalization of $80.27 billion, a price-to-earnings ratio of 18.77, a P/E/G ratio of 28.06 and a beta of 0.21. The firm’s 50-day moving average price is $645.54 and its two-hundred day moving average price is $711.31. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.81 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals will post 2.06 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $26,000. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

  • Positive Sentiment: Analysts continue to see potential upside. Guggenheim raised its price target from $1,000 to $1,030 and maintained a “buy” rating, implying substantial upside. Other firms also lifted their targets to between $750 and $795. Guggenheim price target report
  • Positive Sentiment: Regeneron’s latest quarterly results exceeded expectations, with earnings and revenue above consensus and revenue increasing year over year. The strong performance may help offset concerns about pipeline and product competition.
  • Neutral Sentiment: Citigroup raised its price target from $700 to $740 but retained a “neutral” rating. The revised target remains below the current trading level, signaling limited near-term upside in Citi’s view. Citigroup price target report
  • Negative Sentiment: Several law firms announced or promoted securities class actions against Regeneron and certain executives. The lawsuits allege investors were misled about the Phase III Fianlimab-Libtayo trial, including a protocol change and a failed primary endpoint. The legal claims create reputational, litigation and potential financial risks, although the allegations have not been proven. Regeneron class action announcement
  • Negative Sentiment: Biocon launched Yesafili, a U.S. biosimilar to Regeneron’s Eylea 2 mg. The product could increase pricing pressure and erode sales of a major Regeneron franchise over time. Biocon Yesafili launch

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Further Reading